Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome

The cytoplasmic pattern recognition receptor RIG-I is activated by viral RNA and induces type I IFN responses to control viral replication. The cellular dsRNA binding protein PACT can also activate RIG-I. To counteract innate antiviral responses, some viruses, including Ebola virus (EBOV), encode pr...

Full description

Saved in:
Bibliographic Details
Published in:Cell host & microbe Vol. 14; no. 1; p. 74
Main Authors: Luthra, Priya, Ramanan, Parameshwaran, Mire, Chad E, Weisend, Carla, Tsuda, Yoshimi, Yen, Benjamin, Liu, Gai, Leung, Daisy W, Geisbert, Thomas W, Ebihara, Hideki, Amarasinghe, Gaya K, Basler, Christopher F
Format: Journal Article
Language:English
Published: United States 17.07.2013
Subjects:
ISSN:1934-6069, 1934-6069
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The cytoplasmic pattern recognition receptor RIG-I is activated by viral RNA and induces type I IFN responses to control viral replication. The cellular dsRNA binding protein PACT can also activate RIG-I. To counteract innate antiviral responses, some viruses, including Ebola virus (EBOV), encode proteins that antagonize RIG-I signaling. Here, we show that EBOV VP35 inhibits PACT-induced RIG-I ATPase activity in a dose-dependent manner. The interaction of PACT with RIG-I is disrupted by wild-type VP35, but not by VP35 mutants that are unable to bind PACT. In addition, PACT-VP35 interaction impairs the association between VP35 and the viral polymerase, thereby diminishing viral RNA synthesis and modulating EBOV replication. PACT-deficient cells are defective in IFN induction and are insensitive to VP35 function. These data support a model in which the VP35-PACT interaction is mutually antagonistic and plays a fundamental role in determining the outcome of EBOV infection.
AbstractList The cytoplasmic pattern recognition receptor RIG-I is activated by viral RNA and induces type I IFN responses to control viral replication. The cellular dsRNA binding protein PACT can also activate RIG-I. To counteract innate antiviral responses, some viruses, including Ebola virus (EBOV), encode proteins that antagonize RIG-I signaling. Here, we show that EBOV VP35 inhibits PACT-induced RIG-I ATPase activity in a dose-dependent manner. The interaction of PACT with RIG-I is disrupted by wild-type VP35, but not by VP35 mutants that are unable to bind PACT. In addition, PACT-VP35 interaction impairs the association between VP35 and the viral polymerase, thereby diminishing viral RNA synthesis and modulating EBOV replication. PACT-deficient cells are defective in IFN induction and are insensitive to VP35 function. These data support a model in which the VP35-PACT interaction is mutually antagonistic and plays a fundamental role in determining the outcome of EBOV infection.
The cytoplasmic pattern recognition receptor RIG-I is activated by viral RNA and induces type I IFN responses to control viral replication. The cellular dsRNA binding protein PACT can also activate RIG-I. To counteract innate antiviral responses, some viruses, including Ebola virus (EBOV), encode proteins that antagonize RIG-I signaling. Here, we show that EBOV VP35 inhibits PACT-induced RIG-I ATPase activity in a dose-dependent manner. The interaction of PACT with RIG-I is disrupted by wild-type VP35, but not by VP35 mutants that are unable to bind PACT. In addition, PACT-VP35 interaction impairs the association between VP35 and the viral polymerase, thereby diminishing viral RNA synthesis and modulating EBOV replication. PACT-deficient cells are defective in IFN induction and are insensitive to VP35 function. These data support a model in which the VP35-PACT interaction is mutually antagonistic and plays a fundamental role in determining the outcome of EBOV infection.The cytoplasmic pattern recognition receptor RIG-I is activated by viral RNA and induces type I IFN responses to control viral replication. The cellular dsRNA binding protein PACT can also activate RIG-I. To counteract innate antiviral responses, some viruses, including Ebola virus (EBOV), encode proteins that antagonize RIG-I signaling. Here, we show that EBOV VP35 inhibits PACT-induced RIG-I ATPase activity in a dose-dependent manner. The interaction of PACT with RIG-I is disrupted by wild-type VP35, but not by VP35 mutants that are unable to bind PACT. In addition, PACT-VP35 interaction impairs the association between VP35 and the viral polymerase, thereby diminishing viral RNA synthesis and modulating EBOV replication. PACT-deficient cells are defective in IFN induction and are insensitive to VP35 function. These data support a model in which the VP35-PACT interaction is mutually antagonistic and plays a fundamental role in determining the outcome of EBOV infection.
Author Ebihara, Hideki
Amarasinghe, Gaya K
Mire, Chad E
Yen, Benjamin
Geisbert, Thomas W
Liu, Gai
Basler, Christopher F
Luthra, Priya
Ramanan, Parameshwaran
Tsuda, Yoshimi
Weisend, Carla
Leung, Daisy W
Author_xml – sequence: 1
  givenname: Priya
  surname: Luthra
  fullname: Luthra, Priya
  organization: Department of Microbiology, Icahn School of Medicine at Mount Sinai School, New York, NY 10029, USA
– sequence: 2
  givenname: Parameshwaran
  surname: Ramanan
  fullname: Ramanan, Parameshwaran
– sequence: 3
  givenname: Chad E
  surname: Mire
  fullname: Mire, Chad E
– sequence: 4
  givenname: Carla
  surname: Weisend
  fullname: Weisend, Carla
– sequence: 5
  givenname: Yoshimi
  surname: Tsuda
  fullname: Tsuda, Yoshimi
– sequence: 6
  givenname: Benjamin
  surname: Yen
  fullname: Yen, Benjamin
– sequence: 7
  givenname: Gai
  surname: Liu
  fullname: Liu, Gai
– sequence: 8
  givenname: Daisy W
  surname: Leung
  fullname: Leung, Daisy W
– sequence: 9
  givenname: Thomas W
  surname: Geisbert
  fullname: Geisbert, Thomas W
– sequence: 10
  givenname: Hideki
  surname: Ebihara
  fullname: Ebihara, Hideki
– sequence: 11
  givenname: Gaya K
  surname: Amarasinghe
  fullname: Amarasinghe, Gaya K
– sequence: 12
  givenname: Christopher F
  surname: Basler
  fullname: Basler, Christopher F
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23870315$$D View this record in MEDLINE/PubMed
BookMark eNpNkF1LwzAYhYNM3If-AS8kl9605k3adL0cY87BxCHT25Gkb11Hm8wmnfjvLX6AV-fAeTgczpgMrLNIyDWwGBjIu0Ns9q6JOQMRMxkzYGdkBLlIIslkPvjnh2Ts_YGxNGUZXJAhF9OMCUhH5PjYhU7VVNmg3pytfEM1hg9ES8Me6UK7WtFT1Xaevm5ESo-tC1jZni--gefVMlpRZUJ1UsG1dDObb2mBAdumsuhpZUvsQ2ep64JxDV6S81LVHq9-dUJe7hfb-UO0flqu5rN1ZNI0CRFHLkGZvNRFpnIjMCnBsFKnkEiRZKVJUbFpBsxkmkOSIyugULyQRSL4VGs-Ibc_vf3i9w592DWVN1jXyqLr_A4SAMmlyLMevflFO91gsTu2VaPaz93fS_wL6Ztsxw
CitedBy_id crossref_primary_10_1080_22221751_2024_2341144
crossref_primary_10_3389_fmicb_2020_01990
crossref_primary_10_3390_v16111702
crossref_primary_10_3390_v11050448
crossref_primary_10_1007_s00281_017_0637_x
crossref_primary_10_1016_j_jmb_2025_169366
crossref_primary_10_1016_j_coi_2015_06_003
crossref_primary_10_1016_j_jmb_2016_07_017
crossref_primary_10_1093_infdis_jiad325
crossref_primary_10_1128_jvi_00754_22
crossref_primary_10_1016_j_virusres_2018_02_003
crossref_primary_10_1099_jgv_0_001341
crossref_primary_10_3390_v13122441
crossref_primary_10_1038_ncomms15576
crossref_primary_10_3390_pathogens11121400
crossref_primary_10_1016_j_virol_2015_02_017
crossref_primary_10_1038_s41598_020_58443_3
crossref_primary_10_1128_JVI_00191_16
crossref_primary_10_1038_nrmicro3524
crossref_primary_10_1016_j_virol_2014_12_002
crossref_primary_10_1146_annurev_immunol_042718_041356
crossref_primary_10_1016_j_chom_2013_07_004
crossref_primary_10_1128_MCB_00285_18
crossref_primary_10_1016_j_coviro_2015_02_005
crossref_primary_10_1038_s41401_023_01111_9
crossref_primary_10_3390_v16060821
crossref_primary_10_1371_journal_pone_0178717
crossref_primary_10_3390_ijms241914791
crossref_primary_10_1038_s41423_020_00602_7
crossref_primary_10_1128_JVI_02163_14
crossref_primary_10_1038_s41467_022_29948_4
crossref_primary_10_3390_vaccines5030023
crossref_primary_10_3389_fimmu_2021_694105
crossref_primary_10_1128_JVI_02564_13
crossref_primary_10_3390_v17081082
crossref_primary_10_1128_JVI_03349_14
crossref_primary_10_3389_fimmu_2019_00372
crossref_primary_10_1016_j_antiviral_2018_12_006
crossref_primary_10_1177_2040206619889220
crossref_primary_10_3389_fmicb_2022_1040093
crossref_primary_10_1016_j_jmb_2014_01_010
crossref_primary_10_3390_pathogens10101330
crossref_primary_10_1038_nrmicro_2016_45
crossref_primary_10_1016_j_antiviral_2022_105251
crossref_primary_10_3389_fmicb_2014_00733
crossref_primary_10_1016_j_cytogfr_2014_06_005
crossref_primary_10_1093_infdis_jiv214
crossref_primary_10_1128_JVI_03652_14
crossref_primary_10_1080_15384101_2015_1068472
crossref_primary_10_1371_journal_pntd_0006349
crossref_primary_10_3390_vaccines7040125
crossref_primary_10_1042_BCJ20210110
crossref_primary_10_3390_cells10092399
crossref_primary_10_1038_srep34589
crossref_primary_10_1016_j_antiviral_2018_08_012
crossref_primary_10_1007_s12275_021_0641_7
crossref_primary_10_1016_j_antiviral_2013_10_002
crossref_primary_10_3390_ijms25169007
crossref_primary_10_1042_BCJ20160964
crossref_primary_10_1016_j_immuni_2024_03_003
crossref_primary_10_1128_JVI_00191_20
crossref_primary_10_3390_vaccines7040138
crossref_primary_10_1371_journal_ppat_1005880
crossref_primary_10_1189_jlb_4RI0316_099RR
crossref_primary_10_3390_ijms21041348
crossref_primary_10_1089_ars_2021_0167
crossref_primary_10_1016_j_cell_2014_10_006
crossref_primary_10_1016_j_fsi_2023_109304
crossref_primary_10_1038_s41572_020_0147_3
crossref_primary_10_1038_s41577_020_0288_3
crossref_primary_10_1093_infdis_jiy473
crossref_primary_10_1128_JVI_00830_14
crossref_primary_10_1371_journal_pbio_3002544
crossref_primary_10_1096_fj_201701361R
crossref_primary_10_1128_JVI_03649_13
crossref_primary_10_4049_jimmunol_1601493
crossref_primary_10_1073_pnas_2411961122
crossref_primary_10_1038_nri_2016_138
crossref_primary_10_1016_j_virol_2025_110456
crossref_primary_10_1128_JVI_01995_20
crossref_primary_10_1016_j_coviro_2015_01_004
crossref_primary_10_1128_jvi_01304_23
crossref_primary_10_1371_journal_ppat_1010532
crossref_primary_10_1371_journal_ppat_1010530
crossref_primary_10_1261_rna_079016_121
crossref_primary_10_3390_microorganisms13061397
crossref_primary_10_1016_j_molcel_2025_01_027
crossref_primary_10_3389_fimmu_2022_1010635
crossref_primary_10_1016_j_cell_2018_08_044
crossref_primary_10_1016_j_coph_2021_07_004
crossref_primary_10_1371_journal_pone_0186450
crossref_primary_10_1371_journal_ppat_1005221
crossref_primary_10_1016_j_smim_2015_03_005
crossref_primary_10_1016_j_virol_2015_03_030
crossref_primary_10_1111_imm_13030
crossref_primary_10_1016_j_cytogfr_2014_05_004
crossref_primary_10_1016_j_virol_2017_06_002
crossref_primary_10_1038_ncomms9000
crossref_primary_10_1002_JLB_4RI0518_183R
crossref_primary_10_1016_j_chom_2017_07_012
crossref_primary_10_1128_JVI_00518_18
crossref_primary_10_1007_s40475_015_0039_x
crossref_primary_10_1016_j_coviro_2019_03_001
crossref_primary_10_1016_j_bbrc_2019_10_147
crossref_primary_10_1128_JVI_00482_18
crossref_primary_10_3390_v16050725
crossref_primary_10_1016_j_virol_2015_07_010
crossref_primary_10_1016_j_molcel_2025_04_005
crossref_primary_10_1016_j_jmb_2019_06_002
crossref_primary_10_3390_v10110607
crossref_primary_10_1128_jvi_01954_23
crossref_primary_10_3390_v10020098
crossref_primary_10_3390_biomedicines9070765
crossref_primary_10_1007_s00018_020_03671_z
crossref_primary_10_1371_journal_ppat_1007984
crossref_primary_10_3390_vaccines7010022
crossref_primary_10_1128_JVI_00833_17
crossref_primary_10_1111_febs_13553
crossref_primary_10_1111_febs_15691
crossref_primary_10_1002_wrna_1272
crossref_primary_10_1080_17460913_2025_2501924
crossref_primary_10_3390_pathogens9100850
crossref_primary_10_1128_JVI_02161_15
ContentType Journal Article
Copyright Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2013 Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.chom.2013.06.010
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Biology
EISSN 1934-6069
ExternalDocumentID 23870315
Genre Journal Article
Research Support, N.I.H., Intramural
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: AI093786
– fundername: Intramural NIH HHS
– fundername: NIAID NIH HHS
  grantid: R56 AI093786
– fundername: NIAID NIH HHS
  grantid: R01 AI081914
– fundername: NIAID NIH HHS
  grantid: AI081914
– fundername: NIAID NIH HHS
  grantid: R01 AI059536
– fundername: NIAID NIH HHS
  grantid: AI059536
GroupedDBID ---
--K
0R~
1~5
29B
2WC
4.4
457
4G.
5GY
62-
6J9
7-5
AAEDT
AAEDW
AAIKJ
AAKRW
AALRI
AAMRU
AAVLU
AAXUO
AAYWO
ABDGV
ABJNI
ABMAC
ACGFO
ACGFS
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AEFWE
AENEX
AEUPX
AEXQZ
AFPUW
AFTJW
AGCQF
AGHFR
AGKMS
AIGII
AITUG
AKAPO
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
ASPBG
AVWKF
AZFZN
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EFKBS
EIF
EJD
F5P
FCP
FDB
FEDTE
HVGLF
IHE
IXB
JIG
M41
NPM
O-L
O9-
OK1
P2P
RIG
ROL
RPZ
SES
SSZ
TR2
UNMZH
7X8
ID FETCH-LOGICAL-c554t-2e261ac9fbd7a9c3e4f1c0fb5146347fc5ea08710c7b2149e0d1da2d6d4328bb2
IEDL.DBID 7X8
ISICitedReferencesCount 150
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000330851300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1934-6069
IngestDate Thu Oct 02 09:45:08 EDT 2025
Mon Jul 21 05:43:49 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Copyright © 2013 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c554t-2e261ac9fbd7a9c3e4f1c0fb5146347fc5ea08710c7b2149e0d1da2d6d4328bb2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://www.cell.com/article/S1931312813002266/pdf
PMID 23870315
PQID 1411626397
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1411626397
pubmed_primary_23870315
PublicationCentury 2000
PublicationDate 2013-07-17
PublicationDateYYYYMMDD 2013-07-17
PublicationDate_xml – month: 07
  year: 2013
  text: 2013-07-17
  day: 17
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cell host & microbe
PublicationTitleAlternate Cell Host Microbe
PublicationYear 2013
References 23870307 - Cell Host Microbe. 2013 Jul 17;14(1):5-6
References_xml – reference: 23870307 - Cell Host Microbe. 2013 Jul 17;14(1):5-6
SSID ssj0055071
Score 2.4785979
Snippet The cytoplasmic pattern recognition receptor RIG-I is activated by viral RNA and induces type I IFN responses to control viral replication. The cellular dsRNA...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 74
SubjectTerms Amino Acid Motifs
Cell Line
DEAD Box Protein 58
DEAD-box RNA Helicases - antagonists & inhibitors
DEAD-box RNA Helicases - genetics
DEAD-box RNA Helicases - metabolism
Ebolavirus - chemistry
Ebolavirus - genetics
Ebolavirus - metabolism
Hemorrhagic Fever, Ebola - enzymology
Hemorrhagic Fever, Ebola - genetics
Hemorrhagic Fever, Ebola - metabolism
Hemorrhagic Fever, Ebola - virology
Humans
Protein Binding
Receptors, Immunologic
RNA, Viral - genetics
RNA, Viral - metabolism
RNA-Binding Proteins - antagonists & inhibitors
RNA-Binding Proteins - genetics
RNA-Binding Proteins - metabolism
Viral Regulatory and Accessory Proteins - antagonists & inhibitors
Viral Regulatory and Accessory Proteins - chemistry
Viral Regulatory and Accessory Proteins - genetics
Viral Regulatory and Accessory Proteins - metabolism
Title Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome
URI https://www.ncbi.nlm.nih.gov/pubmed/23870315
https://www.proquest.com/docview/1411626397
Volume 14
WOSCitedRecordID wos000330851300011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwGA3qFHzxfpk3IvgabJu2aZ5kjE0HbhSZY28lt8oebOe6Dvz3fmk7fRIEX_rSBEL6JT1fvpNzELqjhiktI0Uc4Qjia8YJVwIWXqg5VW4YBBU3Z_LMRqNoOuVxc-BWNLTK9Z5YbdQ6V_aM_N71Xdcqp3D2MP8g1jXKVlcbC41N1KIAZWxUs-l3FcFKdbl1VdknANR5c2mm5ndZLxJL7aKVfqfr_A4xq19Nf_-_gzxAew3IxJ06Kg7RhsmO0E5tO_l5jObD0t4awTCp4g3WdPGOG7oWBjiIexLSXbyaLcoCT2Ia4ErLYZZBe101eBk8kgG2NyJWNmXHcac7xrrh1ZgCrwleGc7LJQzcnKDXfm_cfSKN8wJRAC-WxDOQWAnFU6mZ4IoaP3WVk0pAVyH1WaoCIxxItRzFpAc5lnG0q4WnQ-1TL5LSO0VbWZ6Zc4R9xqSIQi7TAF6mgEAkjQAFeco6brC0jW7XU5lAZNtyhchMXhbJz2S20Vn9PZJ5LcGRANCwwvvBxR96X6Jdr_KwsGqYV6iVwro212hbrZazYnFThQw8R_HwCwJoyyA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mutual+antagonism+between+the+Ebola+virus+VP35+protein+and+the+RIG-I+activator+PACT+determines+infection+outcome&rft.jtitle=Cell+host+%26+microbe&rft.au=Luthra%2C+Priya&rft.au=Ramanan%2C+Parameshwaran&rft.au=Mire%2C+Chad+E&rft.au=Weisend%2C+Carla&rft.date=2013-07-17&rft.eissn=1934-6069&rft.volume=14&rft.issue=1&rft.spage=74&rft_id=info:doi/10.1016%2Fj.chom.2013.06.010&rft_id=info%3Apmid%2F23870315&rft_id=info%3Apmid%2F23870315&rft.externalDocID=23870315
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1934-6069&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1934-6069&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1934-6069&client=summon